产品名称	Tocilizumab (anti-IL-6R), 白细胞介素-6 受体抗体
别名	托珠单抗(抗 IL-6R)
英文别名	Q369O8926L \| CHEBI:27881 \| CU-01000001503-3 \| HMS1792H15 \| NSC133100 \| BPBio1_000479 \| NCGC00344093-09 \| RESVERATROL (MART.) \| MLS000069735 \| MLS001076538 \| Stilbene, 2f \| (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol \| MLS002222231 \| TaxusChinensisi
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL-6Ra/CD126
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	白细胞介素-6 受体抗体

AI解读

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.6 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 174.3 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	375823-41-9
分子类型	抗体

图片

ELISA: Tocilizumab (anti-IL-6R) (T412004)

Tocilizumab (anti-IL-6R) (T412004) - ELISA
Immobilized Recombinant Human IL-6R Protein at 2 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC₅₀ of 5.8 ng/mL.

SEC: Tocilizumab (anti-IL-6R) (T412004)

Tocilizumab (anti-IL-6R) (T412004) - SEC
The purity of Tocilizumab (anti-IL-6R) (T412004) is more than 95% verified by HPLC.

ELISA: Tocilizumab (anti-IL-6R) (T412004)

Tocilizumab (anti-IL-6R) (T412004) - ELISA
Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Tocilizumab (anti-IL-6R) (T412004) with the EC50 of 21.05 ng/mL.

关联靶点（人）

IL6R Tclin 白细胞介素-6 受体亚基 α(Interleukin-6 receptor subunit alpha) (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6ST Tclin 白细胞介素-6受体亚基β(Interleukin-6 receptor subunit beta) (0 活性数据)

点击查看靶蛋白信息： IL6ST

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6R Tclin Interleukin-6 receptor alpha subunit (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IL6ST Tclin Interleukin-6 receptor subunit beta (58 活性数据)

点击查看靶蛋白信息： IL6ST

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IL6R Tclin IL6Ralpha/GP130 (4 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

技术规格说明书

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1113671	分析证书	24-11-11	T412004
ZJ24F1113670	分析证书	24-11-11	T412004
ZJ24F1113699	分析证书	24-11-11	T412004
ZJ24F0404271	分析证书	24-04-10	T412004
ZJ24F0404272	分析证书	24-04-10	T412004
ZJ24F0404270	分析证书	24-04-10	T412004

可替换产品

参考文献

1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.. Arthritis Rheum, 54 (9): (2817-29). [PMID:16947782] [10.1021/op500134e]
2. Paul-Pletzer K. (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.. Drugs Today, 42 (9): (559-76). [PMID:17028666] [10.1021/op500134e]
3. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.. Intern Med, 46 (11): (771-4). [PMID:17541233] [10.1021/op500134e]
4. Nishimoto N, Kishimoto T. (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab.. Handb Exp Pharmacol, 71 (181): (151-60). [PMID:18071945] [10.1021/op500134e]
5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.. Int Immunopharmacol, 5 (12): (1731-40). [PMID:16102523] [10.1021/op500134e]
6. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005) Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.. Clin Rev Allergy Immunol, 28 (3): (231-8). [PMID:16129907] [10.1021/op500134e]
7. Ohsugi Y, Kishimoto T. (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.. Expert Opin Biol Ther, 8 (5): (669-81). [PMID:18407769] [10.1021/op500134e]
8. Unizony S, Kermani TA. (2018) IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.. J Neuroophthalmol, 38 (4): (551-558). [PMID:30199509] [10.1021/op500134e]
9. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J et al.. (2021) Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.. JAMA Intern Med, 181 (1): (41-51). [PMID:33080002] [10.1021/op500134e]
10. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C et al.. (2021) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (24-31). [PMID:33080005] [10.1021/op500134e]
11. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. (2021) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (32-40). [PMID:33080017] [10.1021/op500134e]
12. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM et al.. (2020) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.. N Engl J Med, 383 (24): (2333-2344). [PMID:33085857] [10.1021/op500134e]
13. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B et al.. (2020) Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.. Clin Infect Dis, 71 (8): (1937-1942). [PMID:32301997] [10.1021/op500134e]
14. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, Lie P, Huang L, Cheng L, Lin Y et al.. (2020) Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.. J Infect Dis, 222 (9): (1444-1451). [PMID:32601708] [10.1021/op500134e]
15. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e]
16. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e]
17. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182] [10.1021/op500134e]
18. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e]
19. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (13): (135). [PMID:25994180] [10.1021/op500134e]
20. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026]
21. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] [10.1021/jm401144z]
22. Schooltink, H H and 7 more authors.. (1991) Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells.. The Biochemical journal, (1): [PMID:1872801]
23. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M.. (1989) Soluble cytokine receptors are present in normal human urine.. The Journal of experimental medicine, (1): [PMID:2529343]
24. Yamasaki, K K and 8 more authors.. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.. Science (New York, N.Y.), (12): [PMID:3136546]
25. Horiuchi, S S and 8 more authors.. (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.. European journal of immunology, [PMID:8056053]
26. Yawata, H H and 7 more authors.. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.. The EMBO journal, [PMID:8467812]
27. Cole, A R AR and 6 more authors.. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.. The Journal of biological chemistry, (12): [PMID:10066782]
28. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L.. (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells.. Journal of cell science, [PMID:11017875]
29. Nakahara, Hideko H and 6 more authors.. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.. Arthritis and rheumatism, [PMID:12794819]
30. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L.. (2005) Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80.. European journal of cell biology, [PMID:16270750]
31. Gregory, S G SG and 178 more authors.. (2006) The DNA sequence and biological annotation of human chromosome 1.. Nature, (18): [PMID:16710414]
32. Smolen, Josef S JS and Maini, Ravinder N RN.. (2006) Interleukin-6: a new therapeutic target.. Arthritis research & therapy, [PMID:16899109]
33. Reich, David D and 23 more authors.. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.. American journal of human genetics, [PMID:17357077]
34. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW.. (2011) Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.. Blood, (10): [PMID:21940820]
35. Huizinga, Tom W J TW and 9 more authors.. (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.. Annals of the rheumatic diseases, [PMID:24297381]
36. and Lin, Phoebe P.. (2015) Targeting interleukin-6 for noninfectious uveitis.. Clinical ophthalmology (Auckland, N.Z.), [PMID:26392750]
37. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177]
38. June, Rayford R RR and Olsen, Nancy J NJ.. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.. Expert opinion on biological therapy, [PMID:27464017]
39. Riethmueller, Steffen S and 23 more authors.. (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.. PLoS biology, [PMID:28060820]
40. Smolen, Josef S JS and 48 more authors.. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.. Annals of the rheumatic diseases, [PMID:28264816]
41. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003]
42. Kampan, Nirmala Chandralega NC and 5 more authors.. (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.. Current medicinal chemistry, [PMID:28707587]
43. Spencer, Sarah and 37 more authors.. (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.. The Journal of experimental medicine, (2): [PMID:31235509]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Tocilizumab (anti-IL-6R), 白细胞介素-6 受体抗体

库存信息

库存信息

库存信息

库存信息

基本信息

AI解读

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器